Pharmaceutical Executive April 7, 2020
There are approximately 156 anticipated US launches of biotech or pharmaceutical (biopharma) therapies in 2020, including NMEs, NDAs and biosimilars. Of these, 52 are anticipated to launch in Q2, 23 in Q3 and 63 in Q4, based on ZS analysis utilizing Evaluate Pharma data. The top three therapy areas for 2020 launches are central nervous systems, oncology and systemic anti-infectives
With the sudden shift to minimize personal interaction and the refocusing of many hospitals toward COVID-19, cross-functional launch teams must reconsider whether to launch, and if so, how to change their launch execution.
Impact on timing of pharma and biotech launches
The impact of the pandemic will be greatest for launches in Q2 of this year, as...
Today's Sponsors
Today's Sponsor